NEXT GENERATION INVESTMENT BANKING

Members network
Limited Mobile Version
Follow this company and never miss a research update
ORX

Orexo

Research update

Print

Orexo: Zubsolv Rx Data week 9, 2017

Zubsolv tablets showed a market share of 5.49% (5.50%), 4-week rolling average. The total number of Zubsolv tablets sold week 9 (8) reaching 330,203 (308,626). Zubsolv prescriptions (TRx) recorded a market share of 5.50% (5.53%), 4-week rolling average. Number of TRx reaching 11,503 (11,164) during the week. The overall market (buprenorphine/naloxone) show-ed a y/y growth rate of 9.2% (9.0%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 11.2% (11.3%) (4-week rolling average).

Going forward, we will go down in intensity, and only publish prescription data on a monthly basis.

Download full report icon-download